Ceritinib as a promising therapy for ALK related diseases | 合法藥品大搜索

Ceritinib 為口服、高度選擇性且強效的ALK 抑制劑。Ceritinib 在體外及體內會抑制ALK 的自體磷酸化反應、ALK 媒介之下游訊息傳遞蛋白質的磷酸化反應，以及ALK ... Read More

Ceritinib(如Zykadia) (106/9/1、106/11/1、108/7/1) 1.適用於ALK陽性之晚期非小細胞肺癌。(108/7/1) 2.須經事前審查核准後使用： (1)需檢具確實患有非小細胞 ... Read More

2016年3月7日 — Ceritinib 現已核准用於曾接受crizotinib 治療後惡化或無法耐受的ALK 陽性非小. 細胞肺癌。Alectinib 同樣也是第二代ALK 抑制劑，已獲得US FDA 與 ... Read More

Ceritinib (INN, trade name Zykadia /zaɪˈkeɪdiːə/ zy-KAY-dee-ə) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). Read More

Ceritinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell ... Read More

由 ED Deeks 著作 · 2016 · 被引用 13 次 — Ceritinib (Zykadia™) is an oral, selective inhibitor of the anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase which, after genetic rearrangement, acts ... Read More

由 S Li 著作 · 2015 · 被引用 43 次 — Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer. 2015 Mar;16(2):86-91. doi: ... Read More

由 DSW Tan 著作 · 2016 · 被引用 30 次 — Introduction: Crizotinib and ceritinib have been developed to treat advanced or metastatic NSCLC by inhibiting anaplastic lymphoma receptor tyrosine kinase gene ... Read More

Ceritinib is an antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients ... Read More

由 M Ceccon 著作 · 2014 · 被引用 5 次 — Ceritinib, also known as LDK-378 or Zykadia (Novartis), is a second generation inhibitor able to specifically target the anaplastic lymphoma kinase (ALK). Read More